0 065 g of 9 together with 0 047 g tbtu 0 2 ml ethyldiisopropylamine in 2 ml dichloromethane was combined with trans 4 morpholino cyclohexylamine 10 and stirred for 14 hours at 25 u00b0 c then the mixture was diluted with more dichloromethane and the organic phase was extracted with water and potassium carbonate solution then the organic phase was evaporated down and the residue was fractionated by chromatography on silica gel suitable fractions were evaporated down and the residue was crystallised by the addition of ethyl acetate and petroleum ether 50 mg of a white solid were obtained the compounds of general formula i listed in table 1 inter alia are obtained analogously to the procedures described above as has been found the compounds of general formula i are characterised by their wide range of applications in the therapeutic field particular mention should be made of those applications in which the inhibition of specific cell cycle kinases particularly the inhibiting effect on the proliferation of cultivated human tumour cells but also the proliferation of other cells such as endothelial cells for example plays a part as could be demonstrated by dna staining followed by facs analysis the inhibition of proliferation brought about by the compounds according to the invention is mediated by the arrest of the cells particularly at the g2 m phase of the cell cycle the cells arrest depending on the cells used for a specific length of time in this phase of the cell cycle before programmed cell death is initiated an arrest in the g2 m phase of the cell cycle is triggered for example by the inhibition of specific cell cycle kinases in view of their biological.